SRSeth M. Rubin

Seth M. Rubin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Seth M. Rubin has a total of 337 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    E2F1 induces a G0-G1 reentry transcriptional program without changing chromatin accessibility

    by Gerrald A Lodewijk, Benjamin R Topacio, Seungho Lee, Sayaka Kozuki, Alexis Abigail A Alburo, Znala Williams, Clara J Han, Abolfazl Zargari, Tilini U Wijeratne, Neda Bidoki, et al.

    Quiescent cells repress cell-cycle genes via chromatin-based mechanisms to maintain a non-dividing state, yet remain poised to reenter the cell cycle upon stimulation. E2F1, a canonical activator of cell-cycle genes, is sufficient to induce cell-cycle reentry from quiescence, but how it overcomes chromatin-mediated repression remains unclear. Here, we show that inducible E2F1 expression triggers exit from quiescence without changes in chromatin accessibility by harnessing regulatory elements with limited accessibility. Time-resolved transcriptomic analysis demonstrates that E2F1 induces an accelerated transcriptional program compared to serum stimulation. Unlike serum, which triggers broad chromatin remodeling, E2F1 activates genes within a chromatin context with limited accessibility. ChIP-seq analyses reveal that E2F1 binds target sites in quiescent cells to activate canonical cell-cycle genes. Biochemical reconstitution demonstrates that E2F1 binds nucleosomes and accesses DNA wrapped by histones. These findings suggest that E2F1 accesses nucleosome-associated DNA and initiates transcription without major chromatin reorganization. Our work redefines the relationship between transcription factor and chromatin dynamics during fate transitions and establishes E2F1 as a potent regulator capable of inducing cell-cycle reentry without changing chromatin accessibility.

  • Open Access

    The FAM53C/DYRK1A axis regulates the G1/S transition of the cell cycle

    by Taylar Hammond, Jong Bin Choi, Miles W Membreño, Janos Demeter, Roy Ng, Debadrita Bhattacharya, Thuyen N Nguyen, Griffin G Hartmann, Caterina I Colon, Carine Bossard, et al.

    A growing number of therapies are being developed to target the cell cycle machinery for the treatment of cancer and other human diseases. Consequently, a greater understanding of the factors regulating cell cycle progression becomes essential to help enhance the response to these new therapies. Here, using data from the Cancer Dependency Map, we identified FAM53C as a new regulator of cell cycle progression. We found that FAM53C is critical for this cell cycle transition and that it acts upstream of the Cyclin D-CDK4/6-RB axis and of p53 in the regulation of the G1/S transition. By mass spectrometry, biochemical, and cellular assays, we identified and validated DYRK1A as a cell cycle kinase that is inhibited by and directly interacts with FAM53C. Consistent with the role for FAM53C identified in cells in culture, FAM53C knockout human cortical organoids display increased cell cycle arrest and growth defects. Fam53C knockout mice show minor behavioral phenotypes. Because DYRK1A dysregulation contributes to developmental disorders such as Down syndrome as well as tumorigenesis, future strategies aiming at regulating FAM53C activity may benefit a broad range of patients.

  • Open Access

    Distinct PlzC mechanisms integrate chemotaxis and c-di-GMP signaling to regulate Vibrio cholerae motility and biofilm formation

    by Jin Hwan Park, Emily N. Kennedy, Sarvind Tripathi, Avery B. Romp, Seth M. Rubin, Robert B. Bourret, Fitnat H. Yildiz

    Bacterial motility and biofilm formation are essential for the adaptation and survival of Vibrio cholerae , the causative agent of cholera. In many bacterial species, the second messenger c-di-GMP regulates these processes through PilZ domain proteins, however the downstream mechanisms have remained poorly defined. Here, we identify the PilZ domain protein PlzC as a key positive regulator of motility and biofilm formation through distinct mechanisms. A suppressor screen for mutants restoring Δ plzC migration identified downstream regulators, including CheX, a CheY-3 phosphatase. Genetic and phenotypic analyses revealed that PlzC promotes motility by modulating CheX, thereby influencing the frequency of direction changes during swimming. Notably, the role of PlzC in motility regulation is independent of CheZ, another CheY-3 phosphatase, demonstrating that among the two CheY-3 phosphatases, only CheX is under PlzC control. This distinction suggests that CheY-3-P levels are regulated by at least two separate signaling pathways, one of which operates through PlzC. Despite its function in motility, CheX is not required for PlzC-mediated biofilm regulation, indicating pathway specificity. PlzC regulates biofilm formation through a mechanism that involves c-di-GMP binding, separating it from its CheX-dependent motility regulation. Together, our findings establish PlzC as a central regulator linking CheX-mediated motility and c-di-GMP signaling, thereby impacting motility and biofilm formation in V. cholerae .


  • Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy

    by Seth M. Rubin, Julien Sage, Jan M. Skotheim

    At its core, cancer is a disease of uncontrolled cell proliferation mediated by perturbed molecular pathways that have been elucidated over the past few decades. Biochemical and genetic studies have identified the key molecular regulators of the transition from G1 to S phase in the cell cycle that commits cells to division. During the G1/S transition, the cyclin-dependent kinases CDK4 and CDK6 (CDK4/6) form complexes with cyclin D that phosphorylate and inhibit the retinoblastoma protein. The resulting activation of E2F transcription factors then drives progression into S phase. The centrality of the G1/S transition for proliferation motivated the development of small-molecule ATP-competitive CDK4/6 inhibitors, which block the first step of this pathway and are now standard of care for some forms of breast cancer. Although successful, these therapeutics have limitations that have motivated the development of alternative approaches to targeting CDKs and the cell cycle. Here, we review how recently developed inhibitors of CDKs and other components of the G1/S pathway may be used, as single agents or in combination therapies, to oppose the growth of human cancers.


  • Open Access

    E2F1 induces a G0-G1 reentry transcriptional program without changing chromatin accessibility

    by Gerrald A. Lodewijk, Benjamin R. Topacio, Seungho Lee, Sayaka Kozuki, Znala Williams, Clara J. Han, Abolfazl Zargari, Tilini U. Wijeratne, Neda Bidoki, Silvart Arabian, et al.

    Quiescent cells actively repress cell-cycle genes via chromatin-based mechanisms to maintain a non-dividing state, yet remain poised to reenter upon stimulation. E2F1, a canonical activator of cell-cycle genes, is sufficient to induce reentry from quiescence, but how it overcomes chromatin-mediated repression remains unclear. Here, we show that inducible E2F1 expression triggers exit from quiescence and progression through the cycle without changes in chromatin accessibility, by harnessing regulatory elements with limited, pre-existing accessibility. Using time-resolved transcriptomics, we demonstrate that E2F1 induces an accelerated transcriptional program compared to serum. Unlike serum, which triggers broad chromatin remodeling, E2F1-induced activation occurs in a context of limited accessibility. ChIP-seq reveals that E2F1 directly binds target sites in quiescent cells to upregulate canonical genes. Biochemical reconstitution shows that E2F1 binds nucleosomes and accesses internal E2F sites within histone-wrapped DNA. These findings suggest that E2F1 can engage nucleosome-associated DNA and initiate transcription without major chromatin reorganization, redefining transcription factor–chromatin dynamics during cell fate transitions and establishing E2F1 as a potent regulator of cell-cycle reentry.


  • Open Access

    Targeting CDK2 for cancer therapy

    by Erik S. Knudsen, Agnieszka K. Witkiewicz, Ioannis Sanidas, Seth M. Rubin


  • Open Access

    Structural mechanism for the recognition of E2F1 by the ubiquitin ligase adaptor Cyclin F

    by Peter Ngoi, Xianxi Wang, Sivasankar Putta, Ricardo F. Da Luz, Vitor Hugo B. Serrão, Michael J. Emanuele, Seth M. Rubin

    Cyclin F, a noncanonical member of the cyclin protein family, plays a critical role in regulating transitions in the cell division cycle. Unlike canonical cyclins, which bind and activate cyclin-dependent kinases (CDKs), Cyclin F functions as a substrate receptor protein within the Skp1–Cullin-F-box E3 ubiquitin ligase complex, enabling the ubiquitylation of target proteins. The structural features that distinguish Cyclin F as a ligase adaptor and the mechanisms underlying its selective substrate recruitment over Cyclin A, which functions in complex with CDK2 at a similar time in the cell cycle, remain largely unexplored. We utilized single-particle cryoelectron microscopy to elucidate the structure of a Cyclin F–Skp1 complex bound to an E2F1 peptide. The structure and biochemical analysis reveal important differences in the substrate-binding site of Cyclin F compared to Cyclin A. Our findings expand on the canonical cyclin-binding motif (Cy or RxL) and highlight the importance of electrostatics at the E2F1 binding interface, which varies between Cyclin F and Cyclin A. These results advance our understanding of E2F1 regulation and may inform strategies for selectively targeting Cyclin F in cancer or neurodegeneration.


  • Open Access

    Structural and functional analysis of cancer-associated missense variants in the retinoblastoma protein pocket domain

    by Anthony Castro, Alfredo Ruiz Rivera, Chad C. Moorman, Emma R. Wolf-Saxon, Hailey N. Mims, Vanessa I. Vasquez Meza, Matthew A. Rangel, Marcos M. Loera, Ian C. Bond, Seth B. Buchanan, et al.


  • Top Cited Papers
    Open Access

    Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle

    by Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, Yin Wan, Adam P. Dommer, Hanna Rosenheck, Sivasankar Putta, Alec Trub, John Bisi, Jay Strum, et al.

    Cyclin dependent kinase 2 (CDK2) regulates cell cycle and is an emerging target for cancer therapy. There are relatively small numbers of tumor models that exhibit strong dependence on CDK2 and undergo G1 cell cycle arrest following CDK2 inhibition. The expression of P16INK4A and cyclin E1 determines this sensitivity to CDK2 inhibition. The co-expression of these genes occurs in breast cancer patients highlighting their clinical significance as predictive biomarkers for CDK2-targeted therapies. In cancer models that are genetically independent of CDK2, pharmacological inhibitors suppress cell proliferation by inducing 4N cell cycle arrest and increasing the expressions of phospho-CDK1 (Y15) and cyclin B1. CRISPR screens identify CDK2 loss as a mediator of resistance to a CDK2 inhibitor, INX-315. Furthermore, CDK2 deletion reverses the G2/M block induced by CDK2 inhibitors and restores cell proliferation. Complementary drug screens define multiple means to cooperate with CDK2 inhibition beyond G1/S. These include the depletion of mitotic regulators as well as CDK4/6 inhibitors cooperate with CDK2 inhibition in multiple phases of the cell cycle. Overall, this study underscores two fundamentally distinct features of response to CDK2 inhibitors that are conditioned by tumor context and could serve as the basis for differential therapeutic strategies in a wide range of cancers.


  • Differences in Binding Affinity Among Cell-cycle CDK and Cyclin Pairs

    by Sivasankar Putta, Carina A. Villegas, Seth M. Rubin